Biokin Pharmaceutical (688506.SH): T-Bren included in the breakthrough therapy designation list

Zhito Finance APP News: Baili Tianheng (688506.SH) announced that the company's independently developed innovative biologic drug T-Bren (HER2 ADC) is an innovative ADC targeting HER2 with best-in-class potential and has demonstrated significant antitumor efficacy in clinical trials. Its regimen for patients with HER2-expressing locally advanced or metastatic biliary tract cancer who have failed platinum-containing chemotherapy has been included by the Center for Drug Evaluation (CDE) of the National Medical Products Administration in the list of breakthrough therapy designations, and the public notice was recently completed.